Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_917_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •1: SAGES University MASTERS Program: Colorectal Pathway
- •Introduction
- •References
- •Colorectal Surgery Curriculum
- •Facebook™ Groups
- •Conclusion
- •Operative Setup
- •Operating Room Setup
- •Patient Positioning
- •Operative Technique: Surgical Steps
- •Trocar Placement
- •Top-Down Approach
- •Outcomes
- •Conclusions
- •References
- •Operative Setup
- •Operative Technique
- •Port Placement
- •Left/Sigmoid Colectomy
- •Outcomes
- •Conclusions
- •References
- •Operative Setup
- •Operative Technique: Surgical Steps
- •Supramesocolic Approach
- •Inframesocolic Approach
- •Outcomes
- •Conclusions
- •References
- •Bibliography
- •Operative Setup
- •Operative Technique: Surgical Steps
- •Laparoscopic Access
- •Colon Transection
- •Specimen Extraction
- •Anastomosis
- •Fistula Repair
- •Other Steps
- •Outcomes
- •Conclusions
- •References
- •Outcomes
- •Conclusion
- •References
- •Solicit Institutional Support
- •Reviewing Current Data
- •Overcoming Barriers Through Culture Change
- •Conclusions
- •References
- •Conclusion
- •References
- •Preoperative Risk Assessment
- •Special Considerations
- •Immune Suppression
- •Smokers
- •Malnutrition
- •Obesity
- •Renal Impairment
- •Preoperative Stoma Marking
- •Preoperative Patient Education
- •Parenteral Antibiotics
- •Positioning
- •Surgical Time-Out
- •Conclusion
- •References
- •Introduction
- •Preoperative Preparation
- •Laparoscopic Access
- •Special Considerations
- •Complicated Peritoneal Entry
- •Equipment Issues
- •Physiologic Issues
- •Optimizing Laparoscopic Exposure
- •OR Table Positioning
- •Laparoscopic Visualization
- •Splenic Bleeding
- •Organ Injury
- •Small Bowel Injury
- •Ureteral Injury
- •Trocar Site Closure
- •Conclusion
- •References
- •Definitions
- •Central Venous Ligation (CVL)
- •Pathological Outcomes
- •Long-Term Survival
- •Conclusion
- •References
- •12: Unexpected Findings at Appendectomy
- •Inflamed Meckel’s Diverticulum
- •Appendiceal Mass
- •Conclusions
- •References
- •Cecal Diverticulitis
- •Sigmoid Diverticulitis
- •Epiploic Appendagitis
- •Crohn’s Disease
- •Gynecologic Pathology
- •Operative Setup
- •Operative Technique: Surgical Steps, Medial-to-Lateral Approach
- •Outcomes
- •Conclusions
- •References
- •Preoperative Planning
- •Operative Techniques
- •Positioning
- •Trocars Placement
- •Side-to-Side Stapled Anastomosis
- •Side-to-Side Handsewn Anastomosis
- •Side-to-End Stapled Anastomosis
- •Side-to-End Handsewn Anastomosis
- •End-to-Side Handsewn Anastomosis
- •End-to-End Handsewn Anastomosis
- •Operative Time
- •Spillage
- •Alignment/Ergonomics
- •Outcomes
- •Conclusions
- •References
- •Operative Setup
- •da Vinci Xi® Setup (Intuitive Surgical, Sunnyvale, CA, USA)
- •Operative Technique: Surgical Steps
- •Outcomes
- •Conclusions
- •References
- •Operative Setup
- •Complex Crohn’s Disease Resection
- •Crohn’s Fistula
- •Difficult Crohn’s Mesentery
- •Ileocolonic Reconstruction
- •Intracorporeal Anastomosis
- •Extracorporeal Anastomosis
- •Entry
- •Adhesiolysis
- •Thickened Mesentery
- •Anastomotic Problems
- •Postoperative Issues
- •Outcomes
- •Conclusion
- •References
- •Preoperative Optimization
- •Accelerated Recovery Pathway
- •Operative Technique: Surgical Steps
- •Locally Advanced Tumors
- •Outcomes
- •Conclusions
- •References
- •Operative Setup
- •Operative Technique: Surgical Steps
- •Colonic J Pouch
- •Transverse Coloplasty
- •Baker’s Anastomosis
- •Anastomotic Assessment
- •Rectal Stump Blowout
- •Staple Line Bleeding
- •Outcomes
- •Anastomotic Leak
- •Anastomotic Assessment
- •Temporary Fecal Diversion
- •Conclusion
- •References
- •Malignant Diseases
- •Benign Diseases
- •Operative Setup
- •Patient Positioning
- •Room Setup
- •Operative Technique
- •Trocar Placement
- •Si® Robot (Intuitive Surgical, Sunnyvale, CA, USA)
- •Xi® Robot (Intuitive Surgical, Sunnyvale, CA, USA)
- •Si Robot
- •Xi Robot
- •Instrument Insertion
- •Extracorporeal Anastomosis
- •Intracorporeal Anastomosis
- •Instrument Collisions
- •Bleeding
- •Anastomotic Leak
- •Outcomes
- •Conclusions
- •References
- •Operative Technique: Surgical Steps
- •Adhesions
- •Difficult Rectal Stump Dissection
- •Rectal Stump Retraction
- •Outcomes
- •Conclusion
- •References
- •Review Operative Report
- •Review Pathology Report
- •Cross-Sectional Imaging
- •Ureteral Stents
- •Operative Setup
- •Operative Technique: Surgical Steps
- •Outcomes
- •Conclusion
- •References
- •Preoperative Staging
- •Indications and Contraindications
- •Multidisciplinary Management
- •Preoperative Versus Postoperative Chemoradiation
- •Short-Course Radiotherapy
- •Intraoperative Radiation
- •Adjuvant Chemotherapy
- •Total Neoadjuvant Therapy
- •Nonoperative Management
- •Conclusion
- •References
- •Other Equipment/Incisions
- •Splenic Flexure Mobilization
- •Lateral Dissection
- •Pelvic Dissection
- •Outcomes
- •Conclusions
- •References
- •Operative Setup
- •Positioning
- •Port Placement
- •Extraction Site
- •Operative Technique: Surgical Steps
- •Splenic Flexure Release
- •Rectal Mobilization
- •Posterior Dissection
- •Lateral Dissection
- •Anterior Dissection
- •Pelvic Floor Dissection
- •Outcomes
- •Conclusions
- •References
- •Introduction
- •Synchronous Masses/Tumors
- •Meckel’s Diverticulum
- •Peritoneal Carcinomatosis
- •Liver Metastasis
- •Ovarian Mass
- •Malrotation
- •Conclusion
- •References
- •Outcomes
- •Conclusions
- •References
- •Technique
- •Learning Curve
- •Outcomes
- •Conclusions
- •References
- •Operative Strategy
- •Operative Setup
- •Patient Positioning
- •Port Placement
- •Diagnostic Laparoscopy
- •Minimally Invasive Resectional Approach
- •Best Approach
- •Splenic Flexure Mobilization (If Needed)
- •Distal Colon Transection
- •Considerations During Laparoscopic Hartmann’s Procedure
- •Obese Patients
- •Minimally Invasive Non-resectional Approach
- •Laparoscopic Peritoneal Lavage
- •Operative Setup
- •Port Placement
- •Postoperative Management
- •Outcomes
- •Resection
- •Laparoscopic Lavage
- •Conclusions
- •References
- •Outcomes
- •Conclusion
- •References
- •Splenic Flexure Release
- •Colonic Conduit Ischemia
- •Conclusion
- •References
- •Surgeon-Related Factors
- •Bowel Preparation
- •Ureteral Stents
- •Patient Positioning
- •Pneumoperitoneum
- •Laparoscopic Exposure: Trocars
- •Laparoscopic Adhesiolysis

22 Principles ofRectal Cancer Management: Preoperative Staging, Neoadjuvant…
centers, a sizable proportion of patients (as high as 17%) do not complete postoperative chemotherapy [48].
Optimal duration of adjuvant chemotherapy after proctectomy also remains
undetermined. Based on extrapolation from the MOSAIC trial, which led to the
adoption of 6months of FOLFOX as the standard of care for locally advanced colon
cancer, the National Comprehensive Cancer Network guidelines currently recommend a total of 6 months of chemotherapy for rectal cancer. Accounting for the
2months of uoropyrimidine chemotherapy administered concurrently with radiation prior to proctectomy, this translates to approximately 4 months of adjuvant
FOLFOX.
347
Total Neoadjuvant Therapy
In the modern era, patients with rectal cancer more commonly experience distant
metastatic disease than local recurrence, with more than 25% of stage II and III
rectal cancers causing metastatic disease. Although neoadjuvant chemoradiation
has been shown to decrease the incidence of local recurrence, overall survival and
risk of distant metastases are not impacted by chemoradiation. In an effort to prevent distant disease and increase long-term survival, the early introduction of both
chemotherapy and chemoradiation prior to surgery is being investigated. Theoretical
benets include earlier protection against dissemination of micrometastatic disease,
delivery of chemotherapy to the primary tumor with undisrupted vasculature, tumor
downstaging, less toxicity, and better adherence to prescribed treatment.
The novel concept of total neoadjuvant therapy (TNT), in which chemoradiation
and chemotherapy are administered prior to surgery, has been shown to be safe and
effective [49]. A recent retrospective study conducted at Memorial Sloan Kettering
analyzed records of patients treated between 2009 and 2015. Of the 811 patients
identied, 320 received chemoradiation with planned adjuvant chemotherapy, and
308 received TNT (induction FOLFOX-based chemotherapy followed by chemoradiation). Patients in the TNT cohort received greater percentages of the planned
chemotherapy than those in the chemoradiation with planned adjuvant chemotherapy cohort. The rate of complete response, including both pathologic complete
response in patients who underwent surgery and sustained clinical complete
response for at least 12months posttreatment in patients who did not undergo surgery, was 36% in the TNT cohort compared with 21% in the chemoradiation with
planned adjuvant chemotherapy cohort. These ndings provide additional support
for TNT as a viable treatment strategy for rectal cancer. TNT may facilitate nonoperative treatment strategies aimed at organ preservation.
Nonoperative Management
Chemoradiation can lead to pCR, and selected patients with such response can
potentially avoid surgery. This nonoperative management strategy is referred to as
the watch-and-wait approach. Avoiding surgery can potentially lead to better

348
E. Pappou and M. R. Weiser
functional outcomes and better quality of life. The largest systematic study on this
approach was conducted in Brazil [50]. Of 361 patients treated with chemoradiation, 122 attained clinical complete response, and 99 (27%) had sustained complete
regression for at least 1year. Clinical complete response was dened as absence of
residual mass or ulcer on clinical evaluation and endoscopy, as well as no residual
tumor on imaging studies. Of the 99 patients with sustained complete regression,
only 5% developed endoluminal recurrences, none developed pelvic regional recurrence, and 8% developed metastatic disease. Of the 5 patients who developed endoluminal recurrences, 3 underwent salvage APR or low anterior resection, while 2
declined radical surgery and underwent local excision or brachytherapy. The 5-year
rates of overall and disease-free survival were 93% and 85%, respectively.
Retrospective studies conducted in the United Kingdom, the Netherlands, and the
United States reported similar ndings, suggesting that watch-and-wait can be a
reasonable option in carefully selected and closely followed patients [51, 52]. A
number of multi-institutional prospective observational studies and Phase II trials
are currently testing the feasibility of incorporating nonoperative management in
multimodal treatment of rectal cancer, but at the present time, nonoperative management should be considered experimental and should ideally take place in the
setting of a clinical trial.
Conclusion
Decades of basic science and clinical research have resulted in a multitude of treatment options for patients with rectal cancer, providing dramatic improvement
inlocal control and patient survival. Multidisciplinary management of rectal cancer– involving surgical, radiation, and medical oncologists; pathologists; and radiologists – has been shown to improve clinical decision-making and clinical
outcomes. The ability to differentiate levels of risk for tumor recurrence and survival prognoses based on baseline tumor characteristics and response to therapy will
enable future tailoring of treatment to disease biology to reduce morbidity and
improve outcomes.
Acknowledgments The authors thank Arthur Gelmis, editor in the Colorectal Surgery Service at
the Memorial Sloan Kettering Cancer Center, for his assistance in editing this chapter.
References
1. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results
of the MERCURY study. Radiology. 2007;243(1):132–9.
2. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, etal. Rectal cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2017;28(suppl_4):iv22–40.

22 Principles ofRectal Cancer Management: Preoperative Staging, Neoadjuvant…
3. Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, etal. Local
excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal
excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010;17(2):441–7.
4. Shin YS, Yoon YS, Lim SB, Yu CS, Kim TW, Chang HM, et al. Preoperative chemora-
diotherapy followed by local excision in clinical T2N0 rectal cancer. Radiat Oncol J.
2016;34(3):177–85.
5. Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP, etal. Long-term results of
transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the
rectum. J Gastrointest Surg. 2008;12(10):1797–805; discussion 805–6.
6. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, etal. Organ preserva-
tion for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local
excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2
trial. Lancet Oncol. 2015;16(15):1537–46.
7. Maslekar S, Sharma A, Macdonald A, Gunn J, Monson JR, Hartley JE.Mesorectal grades predict
recurrences after curative resection for rectal cancer. Dis Colon Rectum. 2007;50(2):168–75.
8. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken
JH.Macroscopic evaluation of rectal cancer resection specimen: clinical signicance of the
pathologist in quality control. J Clin Oncol. 2002;20(7):1729–34.
9. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C.Low rectal cancer: classication and
standardization of surgery. Dis Colon Rectum. 2013;56(5):560–7.
10. Bonjer HJ, Deijen CL, Haglind EA.Randomized trial of laparoscopic versus open surgery for
rectal cancer. N Engl J Med. 2015;373(2):194.
11. Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, etal. Disease-
free survival and local recurrence after laparoscopic-assisted resection or open resection for
rectal cancer: the Australasian laparoscopic cancer of the rectum randomized clinical trial. Ann
Surg. 2019;269(4):596–602.
12. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, etal. Effect of robotic-
assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among
patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA.
2017;318(16):1569–80.
13. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, et al. Transanal
total mesorectal excision: international registry results of the rst 720 cases. Ann Surg.
2017;266(1):111–7.
14. Lee GC, Sylla P.Shifting paradigms in minimally invasive surgery: applications of transanal
natural orice transluminal endoscopic surgery in colorectal surgery. Clin Colon Rectal Surg.
2015;28(3):181–93.
15. Dietz DW.Multidisciplinary management of rectal cancer: the OSTRICH.J Gastrointest Surg.
2013;17(10):1863–8.
16. Monson JRT, Dietz DW, Boughey JC, You YN.Improving rectal cancer outcomes through
advocacy, education, and research: the OSTRiCh Consortium and the new NAPRC.Bull Am
Coll Surg. 2016;101(11):45–6.
17. Karagkounis G, Stocchi L, Lavery IC, Liska D, Gorgun E, Veniero J, etal. Multidisciplinary
conference and clinical management of rectal cancer. J Am Coll Surg. 2018;226(5):874–80.
18. Khani MH, Smedh K. Centralization of rectal cancer surgery improves long-term survival.
Colorectal Dis. 2010;12(9):874–9.
19. Bulow S, Harling H, Iversen LH, Ladelund S. Improved survival after rectal cancer in
Denmark. Colorectal Dis. 2010;12(7 Online):e37–42.
20. Rombeau JL, Collins JP, Turnbull RB Jr. Left-sided colectomy with retroileal colorectal anas-
tomosis. Arch Surg. 1978;113(8):1004–5.
21. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet.
1993;341(8843):457–60.
22. Enker WE, Thaler HT, Cranor ML, Polyak T.Total mesorectal excision in the operative treat-
ment of carcinoma of the rectum. J Am Coll Surg. 1995;181(4):335–46.
349

350
23. Arbman G, Nilsson E, Hallbook O, Sjodahl R.Local recurrence following total mesorectal
excision for rectal cancer. Br J Surg. 1996;83(3):375–9.
24. Bjerkeset T, Edna TH.Rectal cancer: the inuence of type of operation on local recurrence and
survival. Eur J Surg. 1996;162(8):643–8.
25. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke
experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133(8):894–9.
26. Wibe A, Moller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, etal. A national strategic change
in treatment policy for rectal cancer– implementation of total mesorectal excision as routine
treatment in Norway. A national audit. Dis Colon Rectum. 2002;45(7):857–66.
27. Kapiteijn E, Putter H, van de Velde CJ.Impact of the introduction and training of total meso-
rectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg.
2002;89(9):1142–9.
28. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgi-
cal training programme on outcome of rectal cancer in the County of Stockholm. Stockholm
Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet.
2000;356(9224):93–6.
29. Camilleri-Brennan J, Steele RJ. Quality of life after treatment for rectal cancer. Br J Surg.
1998;85(8):1036–43.
30. Enker WE.Potency, cure, and local control in the operative treatment of rectal cancer. Arch
Surg. 1992;127(12):1396–401; discussion 402.
31. Havenga K, Enker WE, McDermott K, Cohen AM, Minsky BD, Guillem J.Male and female
sexual and urinary function after total mesorectal excision with autonomic nerve preservation
for carcinoma of the rectum. J Am Coll Surg. 1996;182(6):495–502.
32. Shirouzu K, Ogata Y, Araki Y. Oncologic and functional results of total mesorectal exci-
sion and autonomic nerve-preserving operation for advanced lower rectal cancer. Dis Colon
Rectum. 2004;47(9):1442–7.
33. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, etal. Preoperative ver-
sus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.
34. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, etal. Preoperative versus
postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German
CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin
Oncol. 2012;30(16):1926–33.
35. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, etal. Preoperative
multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–30.
36. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced
tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005;23(24):5620–7.
37. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, etal. Chemotherapy
with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.
38. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al.
Preoperative radiotherapy with or without concurrent uorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.
39. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized
trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local
recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial
01.04. J Clin Oncol. 2012;30(31):3827–33.
40. Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, etal. Optimal frac-
tionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm
III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol.
2017;18(3):336–46.
41. Mirnezami R, Chang GJ, Das P, Chandrakumaran K, Tekkis P, Darzi A, et al. Intraoperative
radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, longterm outcomes, and complications. Surg Oncol. 2013;22(1):22–35.
E. Pappou and M. R. Weiser

22 Principles ofRectal Cancer Management: Preoperative Staging, Neoadjuvant…
42. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-
resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal
cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg.
2011;253(4):711–9.
43. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, etal. Neoadjuvant
chemotherapy without routine use of radiation therapy for patients with locally advanced rectal
cancer: a pilot trial. J Clin Oncol. 2014;32(6):513–8.
44. Weiser MR, Fichera A, Schrag D, Boughey JC, You YN.Progress in the PROSPECT trial:
precision treatment for rectal cancer? Bull Am Coll Surg. 2015;100(4):51–2.
45. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adju-
vant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev.
2012;(3):CD004078.
46. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM.Association between
time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic
review and meta-analysis. JAMA. 2011;305(22):2335–42.
47. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, etal. Postoperative che-
motherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance,
Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014;120(8):1162–70.
48. Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, et al.
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated
with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol.
2013;31(1):30–8.
49. Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, etal. Adoption of
total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071.
50. Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al. Patterns of
failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10(10):1319–28; discussion 28–9.
51. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, etal. Assessment of a
watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.
52. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-
wait approach versus surgical resection after chemoradiotherapy for patients with rectal
cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol.
2016;17(2):174–83.
53. Valinluck Lao V, Fichera A.Endorectal ultrasound. In: Chang GJ, editor. Rectal cancer: mod-
ern approaches to treatment. Cham: Springer International Publishing; 2018.
54. Ferrari L, Fichera A.Neoadjuvant chemoradiation therapy and pathological complete response
in rectal cancer. Gastroenterol Rep (Oxf). 2015;3(4):277–88.
55. Hakiman H, Boostrom S, Fleshman J. Total mesorectal excision with autonomic nerve pres-
ervation: “optimized surgery”. In: Long WE, Reddy V, Audisio RA, editors. Modern management of cancer of the rectum. 2nd ed. Cham: Springer International Publishing; 2015.
351

Laparoscopic Low Anterior Resection
forRectal Cancer: TME Planes
23
andSurgery oftheUpper
andMid-Rectum
EricM.Haas andAmandaV.Hayman
Introduction andRationale
Laparoscopic low anterior resection for rectal cancer is one of the more challenging
minimally invasive colorectal procedures to master. The conned and narrow spaces
of the pelvis often limit visualization, exposure, and access. Additionally, it is
imperative to maintain proper planes of dissection to achieve a sound oncologic
resection. Straying from the embryologic planes may result in a eld obscured with
nuisance bleeding and injury to critical structures. It is therefore essential to
approach each case in a stepwise fashion with a clear understanding of the anatomical considerations as well as the precise location of the tumor.
The benets of laparoscopy are well known and include less pain, earlier return
of bowel function, shorter length of stay, and fewer wound complications. With
modern techniques and newer technologies, there is rarely a case that cannot be
approached using laparoscopic technique. More challenging patients including
those with multiple medical morbidities, extreme obesity, or prior open abdominal
procedures, often tend to benet the most. Therefore, our initial approach is to gain
access laparoscopically and assess if all or parts of the procedure can be accomplished in this fashion to limit the morbidity of a large incision.
In the absence of locally advanced disease or a threatened circumferential
resection margin (CRM), upper rectal tumors, and select mid-rectal tumors, are
treated like colon cancers via upfront surgical resection, avoiding the morbidity of
E. M. Haas (*)
Division of Colon and Rectal Surgery, Houston Methodist Hospital, Department of Surgery,
Houston, TX, USA
e-mail: ehaasmd@houstoncolon.com
A. V. Hayman
The Oregon Clinic, Division of Gastrointestinal and Minimally Invasive Surgery,
Oregon Health and Science University, Department of Surgery, Portland, OR, USA
e-mail: ahayman@orclinic.com
© Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020
P. Sylla et al. (eds.), The SAGES Manual of Colorectal Surgery,
https://doi.org/10.1007/978-3-030-24812-3_23
353

354
E. M. Haas and A. V. Hayman
neoadjuvant chemoradiotherapy. Standard oncologic vascular pedicle ligation of the
inferior mesenteric artery (IMA) is performed with regional lymphadenectomy and
is referred to as tumor-specic mesorectal excision (TSME).
However, the delineation between the upper and mid-rectum and the lower rectum can be controversial. Intraoperatively, the top of the rectum can be identied by
where the taenias play and the epiploic appendages peter out. Obviously, this is not
applicable preoperatively. If the tumor is large enough, it can be detected by CT or
MRI, thus providing reliable anatomic landmarks, such as distance from the values
of Houston or the sacral promontory. An approximation of the location of the anterior reection, and thus the delineation between the sigmoid colon and the rectum,
is a line drawn between the top of the sacral promontory and the bottom of the pubic
symphysis. However, in many cases, the exact intraluminal borders of the tumor are
not easily seen on cross-sectional imaging. Therefore, the most important initial
step for the surgeon in the workup for a newly diagnosed rectal cancer is rigid proctoscopy. This is a much more reliable assessment of “true” distance from the anal
verge than exible endoscopy, which should not be solely relied upon for surgical
planning. Marking the tumor distally via tattoo may also aid in identication, intraoperatively, especially if CO
colonoscopy is not readily available. The surgeon
2
should also be aware, however, that occasionally tattoo marks can obscure the anatomical visualization during the minimally invasive procedure. Proctoscopy also
allows the surgeon to determine in which quadrant(s) the tumor is located, which
has implication during resection about what structures would be potentially threatened (i.e., an anterior-based tumor may closely abut or involve the prostate or
vagina). Further, patient habitus may inuence surgical approach. An obese, muscular man may have a longer anal canal, and thus the tumor may be closer to the top
of the anal sphincters (aka the “anorectal ring”) making a laparoscopic approach
more difcult. Proctoscopy also allows for serial assessment of response to neoadjuvant treatment, as well as to detect recurrence during surveillance.
This chapter addresses rectal cancer involving the upper and mid-rectum and,
despite many similarities, leaves out the most distal rectal cancer. For the purposes
of this chapter, we dene the lower rectum as the distal 5cm, the mid-rectum from
6–11 cm, and the upper rectum as above 11 cm (or above the second valve of
Houston). Most studies on rectal cancer dene the top of the rectum as 15cm from
the anal verge [1]. There are several important distinctions between upper and middle rectal cancers. Upper rectal cancers are typically managed with upfront surgical
resection. An adequate distal resection margin and mesorectal excision can be readily achieved with a laparoscopic technique. It is important to understand the anatomical concepts of a tumor-specic mesorectal excision (TSME). To achieve a
TSME, a minimum of 2cm distal margin on the rectum is required, as well as a
5cm distal margin of the mesorectum [2, 3]. Care is taken to avoid the tendency to
cone inward and divide across the mesentery within the required margins.
Mid-rectal cancers are more often subject to neoadjuvant chemoradiation therapy if determined to be locally advanced (Stage II or III disease, i.e., T3 and/or
node-positive disease). TSME is not typically feasible for most tumors of the midrectum due to the constraints of the narrow pelvis and bulky mesentery of the midrectum. In most cases, a total mesorectal excision (TME) with low pelvic colorectal
anastomosis is the most technically feasible approach to surgical resection of

23 Laparoscopic Low Anterior Resection forRectal Cancer: TME Planes andSurgery…
355
mid-rectal cancers. Minimally invasive techniques become much more cumbersome and difcult in these cases and are addressed in the chapters on principles of
rectal cancer and robotic low anterior resection (Chaps. 22 and 24).
Indications andContraindications
A laparoscopic TSME can be considered in many, but not all, patients. Patients with
certain comorbidities, such as extreme obesity or severe pulmonary dysfunction,
may not tolerate prolonged Trendelenburg positioning and/or insufation, as can be
seen intraoperatively by high airway pressures or CO
choose to partially mitigate these concerns by using lower insufation pressures
(such as 10–12mmHg instead of the standard 15), but this may still be insufcient.
Another option is to perform only the splenic exure mobilization laparoscopically,
which typically uses reverse Trendelenburg positioning, and then completing the
pelvic dissection via a Pfannenstiel or lower midline incision. In addition to these
patient factors, there are also tumor characteristics that may make a laparoscopic
approach more challenging: a large, bulky tumor or presence of a colonic stent can
prevent adequate retraction and visualization. Occasionally, adding another assist
port can help, but not always. Additionally, presence of a perforated tumor or
involved radial margins may require dissection outside the standard TME planes.
This can result in a bloodier eld, impeding laparoscopic visualization. Further,
ensuring a negative radial margin in the setting of extreme brosis, such as after an
intense radiation reaction, reoperative surgery, or previous perforation, can be difcult without direct tactile feedback. However, except for patient intolerance of
laparoscopy, the cases listed above are relative contraindications and highly depend
on the skill of the individual surgeon.
If the surgeon is able to maintain the principles of adhering to the avascular
mesorectal planes of dissection, ensure proper radial and distal margins, ensure
proper lymph node harvest to the base of the inferior mesenteric artery (IMA), and
ensure an intact specimen, the laparoscopic approach is appropriate.
retention. The surgeon can
2
Principles andQuality Benchmarks
Ultimately, regardless of the operative approach chosen by the surgeon, a quality
oncologic outcome should never be sacriced. The same quality oncologic benchmarks for TME apply to TSME.As per the National Comprehensive Cancer Network
(NCCN) guidelines and National Accreditation Program in Rectal Cancer (NAPRC)
standards, an adequate lymphadenectomy is a harvest of a minimum of 12 lymph
nodes. The commonly accepted distances to be considered an adequate margin are as
follows: radial (>1mm), distal (2cm), and mesenteric (5cm) [3]. Although the exact
factors that predispose for low anterior resection syndrome (bowel dysfunction characterized by stool clustering, increased frequency, urgency, or incomplete emptying)
are multifactorial, taking care to preserve the paired hypogastric nerves that run
along the back of the rectum distal to the sacral promontory may mitigate this risk.
Because of this risk, it is important to preoperatively assess the patient’s bowel

356
E. M. Haas and A. V. Hayman
function and at all future postoperative appointments. There are many validated
questionnaires that assess patient-reported outcomes regarding bowel function,
including the FIQOL (fecal incontinence quality of life), the MSKCC bowel function
instrument, or the EORTC QOL questionnaire for colorectal cancer surgery
(QLQ-CR38). Sexual function may also be impaired postoperatively, likely due to
injury to the nervi erigentes that course horizontally near the lateral rectal stalks.
Although the surgeon will not be performing a complete mesorectal excision, the
same avascular presacral plane needs to be maintained while keeping the fascia
propria of the mesorectum intact. Similar to the surgical principles of a TME, it is
essential to not “cone in” on the mesentery when planning where to perform the
rectal transection. It is also essential to harvest the lymph nodes at the base of the
IMA and maintain the dissection into the retroperitoneal planes along the superior
rectal artery leading to the mesorectal dissection.
Preoperative Planning, Patient Workup, andOptimization
The initial workup includes serum CEA level and CT scan of the chest, abdomen,
and pelvis to rule out metastatic disease as per NCCN guidelines. Rigid proctoscopy
is performed to assess clinical features of the cancer including measurement of the
precise distance from the anal verge. Locoregional staging evaluation is performed
with MRI using a rectal cancer staging protocol, unless MRI is medically contraindicated. Per NAPRC guidelines, endorectal ultrasound is considered an inferior staging option, due to the lack of reproducibility and inability to serially assess radial
margins in a multidisciplinary fashion. [4] Based on the assessment, decision is rendered to proceed with neoadjuvant therapy followed by surgical resection versus
immediate surgical resection. Each rectal cancer case should be presented for consensus recommendations in the setting of a multidisciplinary tumor conference.
Managing perioperative risks are essential. All diabetic patients must have good
perioperative glucose management, as reected by a preoperative Hba1c level. If elevated (>7.5%), aggressive comanagement with their endocrinologist is recommended.
Additional modiable risk factors such as tobacco and alcohol use should be addressed
with a cessation program in the allotted time period prior to the resection. Nutritional
optimization should also be addressed and maximized, and obese patients are encouraged to lose excess weight. Preoperatively, all patients undergo oral antibiotics and
mechanical bowel preparation, as well as a standardized enhanced recovery protocol
that includes multimodal pain regimen, early feeding, goal-directed uid therapy to
minimize IV uids, and early mobilization. For additional details, please refer to
Chaps. 7 and 8 on enhanced recovery protocols in colorectal surgery.
Although we do not routinely utilize ureteral stents, consideration of placement
is important in cases that involve difcult pelvic anatomy such as a redo pelvic surgery or selected patients with T4 disease or history of perforated tumor. Lastly, if an
ileostomy is planned (i.e., when performing a low pelvic anastomosis within 5cm
from the anal verge or following neoadjuvant radiation or in the setting of malnutrition or immunosuppression), patients should meet with a wound ostomy nurse preoperatively for education and stoma marking.

Monitor
23 Laparoscopic Low Anterior Resection forRectal Cancer: TME Planes andSurgery…
357
Room Setup andPatient Positioning
The most common laparoscopic approach is multiport surgery with the placement
of four or ve ports. Reduced port techniques are feasible and included below.
Single-port laparoscopic surgery can be performed, but anatomical constraints of
the lower pelvic anatomy result in less-than-ideal exposure and access with this
approach. Another approach, which can be especially useful is the morbidly
obese, is a hand-assisted technique via either a Pfannenstiel or lower midline
approach. The patient is secured to safely enable steep Trendelenburg and leftside elevation throughout the procedure. This should be ensured by a preoperative
“Trendelenburg test.”
Intraoperative Positioning (Fig.23.1)
• Both arms tucked
• Modied lithotomy or split leg
• 5 (or 10) mm camera port at umbilicus
• 5mm ports in right upper quadrant (RUQ) and right lower quadrant (RLQ)
• Optional 5mm port in left lower quadrant (LLQ) or subxiphoid
Assistant
Surgeon
Fig. 23.1 Surgeon and room setup
Monitor
Surgical
tech
Back table
Соседние файлы в папке Библиотека им академика М.И. Перельмана
